Sen. John Boozman Sells Off Shares of AbbVie Inc. (NYSE:ABBV)

Key Points

• Senator John Boozman sold shares of AbbVie Inc. (NYSE:ABBV) valued between $1,001 and $15,000 on August 11th, which was disclosed on September 12th.
• AbbVie recently missed its earnings per share target, reporting $2.97, below the expected $3.24, but its revenue for the quarter was $15.42 billion, surpassing the $14.93 billion estimate.
• The company has declared a quarterly dividend of $1.64, payable on November 14th, which represents a yield of 3.0% and highlights a relatively high dividend payout ratio of 312.38%.

Senator John Boozman (R-Arkansas) recently sold shares of AbbVie Inc. NYSE: ABBV. In a filing disclosed on September 12th, the Senator disclosed that they had sold between $1,001 and $15,000 in AbbVie stock on August 11th.

Senator John Boozman also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of NVIDIA NASDAQ: NVDA on 8/22/2025.
• Sold $1,001 - $15,000 in shares of AbbVie NYSE: ABBV on 8/22/2025.
• Sold $1,001 - $15,000 in shares of Micron Technology NASDAQ: MU on 8/22/2025.
• Purchased $1,001 - $15,000 in shares of Eli Lilly and Company NYSE: LLY on 8/22/2025.
• Purchased $1,001 - $15,000 in shares of Eli Lilly and Company NYSE: LLY on 8/11/2025.
• Purchased $1,001 - $15,000 in shares of Advanced Micro Devices NASDAQ: AMD on 8/7/2025.
• Purchased $1,001 - $15,000 in shares of iShares MBS ETF NASDAQ: MBB on 8/1/2025.
• Sold $1,001 - $15,000 in shares of iShares MSCI EAFE ETF NYSEARCA: EFA on 8/1/2025.
• Purchased $1,001 - $15,000 in shares of Goldman Sachs ActiveBeta Emerging Markets Equity ETF NYSEARCA: GEM on 8/1/2025.
• Purchased $1,001 - $15,000 in shares of iShares 7-10 Year Treasury Bond ETF NASDAQ: IEF on 8/1/2025.

AbbVie Trading Down 0.8%

Shares of AbbVie stock opened at $218.40 on Monday. The company has a market capitalization of $385.82 billion, a P/E ratio of 104.00, a P/E/G ratio of 1.40 and a beta of 0.53. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. The company has a fifty day moving average of $200.25 and a 200 day moving average of $194.45. AbbVie Inc. has a fifty-two week low of $163.81 and a fifty-two week high of $221.76.

AbbVie (NYSE:ABBV - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $2.97 earnings per share for the quarter, missing the consensus estimate of $3.24 by ($0.27). The firm had revenue of $15.42 billion during the quarter, compared to the consensus estimate of $14.93 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The company's quarterly revenue was up 6.6% on a year-over-year basis. During the same period in the prior year, the company posted $2.65 EPS. On average, sell-side analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, November 14th. Investors of record on Wednesday, October 15th will be issued a $1.64 dividend. The ex-dividend date of this dividend is Wednesday, October 15th. This represents a $6.56 annualized dividend and a yield of 3.0%. AbbVie's dividend payout ratio is currently 312.38%.

Wall Street Analyst Weigh In

Several brokerages have commented on ABBV. Wells Fargo & Company boosted their price target on shares of AbbVie from $240.00 to $260.00 and gave the stock an "overweight" rating in a research note on Friday. Bank of America boosted their price target on shares of AbbVie to $204.00 and gave the stock a "hold" rating in a research note on Monday, June 9th. Guggenheim upped their target price on shares of AbbVie from $216.00 to $227.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Wall Street Zen cut shares of AbbVie from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 22nd. Finally, Raymond James Financial restated an "outperform" rating on shares of AbbVie in a research report on Monday, August 25th. Four analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $217.10.

Institutional Trading of AbbVie

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Marshall & Sullivan Inc. WA bought a new position in AbbVie in the 2nd quarter worth about $25,000. Evolution Wealth Management Inc. bought a new position in shares of AbbVie during the second quarter valued at approximately $26,000. TD Capital Management LLC boosted its stake in shares of AbbVie by 82.9% during the first quarter. TD Capital Management LLC now owns 128 shares of the company's stock valued at $27,000 after purchasing an additional 58 shares in the last quarter. Spurstone Advisory Services LLC bought a new position in shares of AbbVie during the second quarter valued at approximately $28,000. Finally, Abound Financial LLC bought a new position in shares of AbbVie during the first quarter valued at approximately $30,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, EVP Nicholas Donoghoe sold 13,295 shares of the stock in a transaction that occurred on Tuesday, August 5th. The shares were sold at an average price of $198.51, for a total transaction of $2,639,190.45. Following the transaction, the executive vice president directly owned 58,247 shares in the company, valued at approximately $11,562,611.97. This trade represents a 18.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Azita Saleki-Gerhardt sold 42,370 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the transaction, the executive vice president owned 177,292 shares in the company, valued at approximately $35,178,278.64. This represents a 19.29% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.08% of the stock is currently owned by company insiders.

About Senator Boozman

John Boozman (Republican Party) is a member of the U.S. Senate from Arkansas. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Boozman (Republican Party) ran for re-election to the U.S. Senate to represent Arkansas. He won in the general election on November 8, 2022. Boozman won re-election in 2016. He faced Democrat Conner Eldridge, Libertarian Frank Gilbert, and write-in candidate Jason Tate in the general election. Arkansas' U.S. Senate race was rated as safely Republican in 2016. Boozman began his political career in the U.S. House. He won a special election in 2001 and served in that position until his election to the Senate in 2010. Prior to his political career, Boozman worked as an optometrist. As of a 2014 analysis of multiple outside rankings, Boozman is an average Republican member of Congress, meaning he will vote with the Republican Party on the majority of bills. Below is an abbreviated outline of Boozman's academic, professional, and political career: 2011-Present: U.S. Senator from Arkansas 2001-2011: U.S. Representative from Arkansas 1977: Graduated from Southern College of Optometry

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.